A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).

Inclusion Criteria

• Inclusion Criteria: (Both Part I and Part II) - Age >= 18 years at time of signing informed consent form - ECOG performance status of 0 or 1 - Patients with a locally advanced, recurrent, or metastatic solid tumor for which standard therapy either does not exist or has proven ineffective or intolerable (Part I only) - Patients with measurable and/or evaluable disease per RECIST v1.1 - Patients with MAPK pathway alterations positive solid tumor (i.e., BRAF, K/N/H-RAS mutations) (Part II only) - Patients with measurable disease per RECIST v1.1 - Patients with KRAS mutated NSCLC (NSCLC cohort) - Patients with KRAS mutated Ovarian Cancer (Ovarian Cancer cohort) - Patients with RAS mutated solid tumor (Biopsy cohort) Exclusion Criteria: (Both Part I and Part II) - Significant cardiovascular disease, such as New York Heart Association (NYHA) cardiac disease (Class II or greater), unstable angina, or myocardial infarction within the previous 6 months or unstable arrhythmias within the previous 3 months - Patients with primary central nervous system (CNS) malignancy, untreated CNS metastases requiring any anti-tumor treatment, or active CNS metastases - Patients with current severe, uncontrolled systemic disease (including, but not limited to, clinically significant cardiovascular disease, pulmonary disease, or renal disease, ongoing or active infection) - Patients with a history or complication of interstitial lung disease (ILD)